Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Recruiting · NCT07151040 · Interventional (participants receive a specific treatment) · Lead sponsor: One-carbon Therapeutics AB
View the official record on ClinicalTrials.gov →Interventions studied
TH9619
What this trial is about
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Must have given written informed consent
- Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer))
- Prior treatment with at least one line of cytotoxic systemic therapy for metastatic/unresectable cancer
- Adult patients (≥18 years of age)
- Must be willing to comply with study procedures
Exclusion criteria
- History or presence of any clinically significant disorders as judged by the Investigator.
Where it is running
4 locations listed.
- Vall D Hebron Institute Of Oncology - Barcelona, Spain
- Hospital Universitario Fundacion Jimenez Diaz - Madrid, Spain
- Newcastle University - Newcastle upon Tyne, United Kingdom
- Institut Gustave Roussy - Villejuif, France